Medtronic’s Stanton Stresses The Downsides Of Cost-Effectiveness Analyses
This article was originally published in The Gray Sheet
Executive Summary
Cost-effectiveness analysis should not be included in Medicare coverage because the methodology is "too immature" and lacks a universal threshold for how much a quality life-year is worth, according to Medtronic Medical Director Marshall Stanton, MD